Stability of Prostacyclin in Human Plasma and Whole Blood: Studies on the Protective Effect of Albumin

Summary

The biological half-life of prostacyclin in Krebs solution, human cell-free plasma or whole blood was measured by bracket assay on ADP-induced platelet aggregation. At 37°C, pH 7.4, plasma and blood reduced the rate of loss of antiaggregatory activity compared with Krebs solution. The protective effect of plasma was greater than that of whole blood. This effect could be partially mimicked by the addition of human or bovine serum albumin to the Krebs solution. The stabilisation afforded by human serum albumin was dependent on the fatty acid content of the albumin, although this was less important for bovine serum albumin.

Keywords

Prostacyclin half-life - Serum albumins - Platelet aggregation

• References

• 1 Moncada S, Higgs EA, Vane JR. Human arterial and venous tissues generate prostacyclin (prostaglandin X) a potent inhibitor of platelet aggregation. Lancet 1977; 1: 18-20
• 2 Whittle BJ, Moncada S, Vane JR. Comparison of the effects of prostacyclin (PGI₂), prostaglandin Ex and D₂ on platelet aggregation in different species. Prostaglandins 1978; 16: 373-388
• 3 Cho MJ, Allen MA. Chemical stability of prostacyclin (PGI₂) in aqueous solutions. Prostaglandins 1978; 15: 943-954
• 4 Pedersen KA, Stoffersen E, Dyerberg J. Stability of prostacyclin in plasma. Lancet 1979; 1: 1352
• 5 El Tahir KE H, Betteridge DJ, Reckless JP, Williams KI. Stability of prostacyclin in human plasma. Clin Sci 1980; 59: 28-29
• 6 Borda ES, Lazzari MA, Gimeno MF, Gimeno AL. Human platelet rich plasma and human serum protects from inactivation the antiaggregatory capacity of prostacyclin-like material (PGI₂) produced by the rat stomach fundus. Prostaglandins 1980; 19: 899-905
• 7 MacIntyre D, Steer M, Galgoci B, Khorana J, Levine L, Salzman E. Removal or decay of PI reverses its effect on platelet cAMP levels and platelet aggregation. Abstracts of the Fourth Int Prostaglandin Conf 1979; Abstract 73 a
• 8 O’Grady J, Warrington S, Moti MJ, Bunting S, Flower R, Fowle AS, Higgs EA, Moncada S. Effects of intravenous infusion of prostacyclin in man. Prostaglandins 1980; 19: 319-332
• 9 Smith JB, Ingerman C, Silver MJ. Persistence of thromboxane A₂- like material and platelet release-inducing activity in plasma. J Clin Invest 1976; 58: 1119-1122
• 10 Lagarde M, Velardo B, Blanc M, Dechavanne M. Fatty acids bound to albumin decrease the half-life of thromboxane A₂ . Prostaglandins 1980; 20: 275-283
• 11 Folco G, Grandstrom E, Kindahl H. Albumin stabilises thromboxane A₂ . FEBS Letters 1977; 82: 321-324
• 12 Orchard MA, Robinson C. Prostacyclin is stabilised by serum albumin. Br J Pharmacol 1981; 74: 206
• 13 Dusting GJ, Moncada S, Vane JR. Recirculation of prostacyclin (PGI₂) in the dog. Br J Pharmacol 1978; 64: 315-320
• 14 Wynalda MA, Fitzpatrick FA. Albumins stabilise prostaglandin I₂ . Prostaglandins 1980; 20: 853-861
• 15 Pifer DD, Cagen LM. Chesney C Mcl. Stability of prostaglandin I₂ in human blood. Prostaglandins 1981; 21: 165-175
• 16 Rao GH, Reddy KR, Hagert K, White JG. Influence of pH on the prostacyclin (PGI₂) mediated inhibition of platelet function. Prostaglandins Med 1980; 4: 263-273
• 17 Birkett DJ, Myers SP, Sudlow G. The fatty acid content and drug binding characteristics of commercial albumin preparations. Clin Chim Act 1978; 85: 253-258
• 18 Gueriguian JL. Noncovalent binding of prostaglandins A₁, E₁ F₂α and E₂ by human and bovine serum albumins. J Pharmacol Exper Ther 1976; 197: 319-401
• 19 Spector AA. Fatty acid binding to plasma albumin. J Lipid Res 1975; 16: 165-176
• 20 Chiang Y, Kresge AJ, Cho MJ. Acid-catalysed hydrolysis of prostacyclin: origin of the unused lability. J C S Chem Comm 1979; 129-130
• 21 McClenaghan MD, Haslam RJ. A sensitive assay for prostacyclin (PGI2) applicable to fresh rabbit blood. Fed Proc 1980; 39: 323
• 22 Willems Ch, van Aken WG, van Mourik JA. Binding of prostacyclin (PGI2) to human erythrocytes. Acta Therapeutica 1980; 6 (suppl) 31
• 23 Baroody RA, Bito LZ. The impermeability of the basic cell membrane to thromboxane B₂, prostacyclin and 6-keto-PGF_1α . Prostaglandins 1981; 21: 133-142